Program Overview
This CME/CNE activity will review recent advances in the treatment and management of chronic obstructive pulmonary disease (COPD) as presented at the American Thoracic Society (ATS) 2018 Conference in San Diego, California. Three expert faculty will review the Global Initiative for Chronic Obstructive Lung Disease (GOLD) Guidelines, highlighting the significant changes over the last two years and their implications in clinical practice. Current clinical trial data in COPD will be analyzed, with an emphasis on nebulized long-acting muscarinic antagonists (LAMA) and LAMA/Long-Acting Beta2-Agonists (LABA) bronchodilators. Critical elements of an interprofessional care model to optimize patient engagement, care and outcomes will be relayed. Upon completing this education, learners will better understand how to provide optimal, comprehensive care for their COPD patients.
Target Audience
Pulmonologists, internists, nurse practitioners, nurses, and other healthcare professionals involved in the management of patients with COPD
Learning Objectives
1. Manage persistent respiratory symptoms and airflow limitations to better diagnose patients with COPD
2. Apply recent clinical trial data, including LAMA and LAMA/LABA bronchodilators in clinical practice
3. Utilize the healthcare team to develop patient specific treatment plans to improve respiratory symptoms and airflow in patients with COPD
Faculty
Sidney Braman, MD (Course Chair)
Professor of Medicine
Icahn School of Medicine at Mount Sinai
Mount Sinai National Jewish Health Respiratory Institute
New York, New York
Reynold Panettieri, Jr., MD
Professor of Medicine, Robert Wood Johnson Medical School
Vice Chancellor, Clinical & Translational Science
Director, Rutgers Institute for Translational Medicine & Science
New Brunswick, New Jersey
Emeritus Professor of Medicine, University of Pennsylvania
Philadelphia, Pennsylvania
Abby Schwartz, RN, BSN, MBA
Vice President
The Mount Sinai Medical Center
New York, New York
Disclosures of Conflict of Interest
It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CNE activity:
| Faculty | Relationship Identified With: |
| Sidney Braman, MD | Speaker’s Bureau: Genentech, Inc. |
| Reynold Panettieri, Jr., MD | Consultant/Advisor: AstraZeneca; Boehringer Ingelheim; MedImmune; Novartis Pharmaceuticals CorporationGrant/Research Support: AstraZeneca; Bristol-Myers Squibb; Genentech, Inc.; Gilead; MedImmune; OncoArendi Therapeutics; RFIM; Sanofi Genzyme and Regeneron; Theratrophix; Vertex Pharmaceuticals CorporationSpeaker’s Bureau: AstraZeneca; MedImmune; Sanofi Genzyme and Regeneron; Teva Pharmaceutical Industries Ltd. |
| Abby Schwartz, RN, BSN, MBA | Nothing to disclose. |
Planners, Managers, Reviewers
Timothy Hayes, MD, PhD; Emma Boring; Nicole Brestowski and Kim Cheramie, MSN, RN-BC hereby state that they or their spouse/life partner do not have any financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.
Accreditation Statement
AcademicCME designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
AcademicCME designates this enduring material for a maximum of 1.0 CNE contact hour.
Credit Designation Statement
AcademicCME designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
AcademicCME designates this enduring material for a maximum of 1.0 CNE contact hour (1.0 CNE pharmacotherapeutic contact hour).
Financial Support
This activity has been supported by an independent educational grant from Sunovion Pharmaceuticals Inc.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and Sunovion Pharmaceuticals Inc. do not recommend the use of any agent outside of the labeled indications.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Method of Participation
1. Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
2. Complete the Pre-Activity Questions.
3. Read or Review the activity content.
4. Complete the Post-Activity Test Questions and Evaluation.
5. Healthcare providers who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a CME/CNE Certificate.
6. All other participants who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a Certificate of Participation.
7.Healthcare providers should claim only the credit commensurate with the extent of their participation in the activity.
8. 60 minutes of participation = 1 CNE contact hour
CE Inquiries/Special Needs
For all CME/CNE inquiries or special needs, please contact [email protected].
